Anika Therapeutics, Inc. (ANIK)

28,36 +0,50 (+1,79%) Alla chiusura: 04:00PM EDT

Anika Therapeutics, Inc.

32 Wiggins Avenue
Bedford, MA 01730
United States
781 457 9000
https://www.anika.com

Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 357

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Cheryl Renee Blanchard Ph.D.	President, CEO & Director	1,34M	N/D	1964
Mr. Michael L. Levitz	Executive VP, CFO & Treasurer	734,14k	N/D	1974
Ms. Anne Nunes	Senior VP & COO	625,05k	N/D	1969
Mr. David Colleran J.D.	Executive VP, General Counsel & Corporate Secretary	696,85k	N/D	1972
Mr. Ian W. McLeod	VP & Chief Accounting Officer	N/D	N/D	N/D
Mr. Mark Namaroff	Executive Director of Investor Relations & Corporate Communications	N/D	N/D	1963
Mr. James Chase	Senior Vice President of International Sales & Marketing	N/D	N/D	N/D
Mr. Ben Joseph	Vice President of Commercial & Corporate Development	N/D	N/D	N/D
Ms. Lisa Funiciello	Vice President of Human Resources	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Anika Therapeutics, Inc. al 1 maggio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 2; diritti degli azionisti: 5; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.